Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [electronic resource]

By:

Hartsough, Edward J

Contributor(s):

Kugel, Curtis H
Vido, Michael J
Berger, Adam C
Purwin, Timothy J
Goldberg, Allison
Davies, Michael A
Schiewer, Matthew J
Knudsen, Karen E
Bollag, Gideon
Aplin, Andrew E

Producer: 20190305Description: 84-95 p. digitalISSN:

1538-8514

Subject(s):

Animals
Cell Line, Tumor
Female
Humans
Melanoma -- drug therapy
Mice, Nude
Protein Kinase Inhibitors -- pharmacology
Proto-Oncogene Proteins B-raf -- genetics

Online resources:

Available from publisher's website

In: Molecular cancer therapeutics vol. 17

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

There are no comments on this title.

Browse results Close

Back to results

1 A review of health related quality of life in systemic lupus erythematosus.
by McElhone, K
2 GMDP and psoriasis.
by Bhushan, M
3 Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study.
by McElhone, K
4 Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
by Bhushan, M
5 The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women.
by Buckler, H M
6 Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being.
by Fortune, D G
7 Lupus-specific health outcome measure for US patients: the LupusQoL-US version.
by Jolly, M
8 The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
by Burden, A D
9 Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.
by Iskandar, I Y K
10 Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.
by Davison, N J
11 Biaryl diacid inhibitors of human s-PLA2 with anti-inflammatory activity.
by Springer, D M
12 Is the Disease-Specific Lupusqol Sensitive To Changes of Disease Activity In Systemic Lupus Erythematosus Patients After Treatment of A Flare?
by McElhone, K
13 Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
by Iskandar, I Y K
14 A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
by Yiu, Z Z N
15 Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
by Yiu, Z Z N
16 Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
by Iskandar, I Y K
17 Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
by Mason, K J

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas

APA

Hartsough E. J., Kugel C. H., Vido M. J., Berger A. C., Purwin T. J., Goldberg A., Davies M. A., Schiewer M. J., Knudsen K. E., Bollag G. & Aplin A. E. (20190305). Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas. : Molecular cancer therapeutics.

Chicago

Hartsough Edward J, Kugel Curtis H, Vido Michael J, Berger Adam C, Purwin Timothy J, Goldberg Allison, Davies Michael A, Schiewer Matthew J, Knudsen Karen E, Bollag Gideon and Aplin Andrew E. 20190305. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas. : Molecular cancer therapeutics.

Harvard

Hartsough E. J., Kugel C. H., Vido M. J., Berger A. C., Purwin T. J., Goldberg A., Davies M. A., Schiewer M. J., Knudsen K. E., Bollag G. and Aplin A. E. (20190305). Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas. : Molecular cancer therapeutics.

MLA

Hartsough Edward J, Kugel Curtis H, Vido Michael J, Berger Adam C, Purwin Timothy J, Goldberg Allison, Davies Michael A, Schiewer Matthew J, Knudsen Karen E, Bollag Gideon and Aplin Andrew E. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas. : Molecular cancer therapeutics. 20190305.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC